Tag: oncology
Business Finland granted Sartar R&D Funding
20.9.2021
We are proud to inform that the national innovation funding body Business Finland has granted R&D funding for Sartar Therapeutics. This R&D loan will allow us to advance the development of our product SAR001 towards clinical trials. We consider this positive decision as a significant credit for our technology for the treatment of soft tissue sarcomas.
Sartar’s therapy method featured in Drug Target Review
20.7.2021
Targeting phosphodiesterase 3A: discovery of a promising cancer therapy in Drug Target Review describes the science behind Sartar’s new cancer therapy, outlining emerging evidence that PDE3A protein-targeting compounds may induce sarcoma cell death by acting as a molecular glue between PDE3A and Schlafen 12 proteins. Link to original article